Summary of the Conference Call on Rebio Biotech Company Overview - Rebio Biotech (06938) is a global leader in small nucleic acid drug development, with a proven and mature drug development platform [2][3]. Key Points - **Development Platform**: The company has developed the GalNAc liver-targeting RiboGalSTAR platform, which has evolved from liver-targeting to extrahepatic targeting. Continuous chemical modifications enhance target specificity and sequence compatibility while reducing off-target effects, improving efficacy and safety [2][3]. - **Intellectual Property**: As of the end of 2025, Rebio holds 473 patents and patent applications across major jurisdictions, establishing a comprehensive intellectual property portfolio [4]. - **Full Lifecycle Coverage**: The R&D platform integrates the entire technical chain, ensuring efficiency from CMC production and early research to commercialization [4]. - **Clinical Assets**: Rebio is one of the Chinese small nucleic acid companies with the most clinical assets. By the end of 2025, the company has seven siRNA pipelines in clinical stages, with four in Phase II. Key assets include: - RBD4059 (FXI): The world's first and fastest clinical progress siRNA drug for thrombotic diseases, expected to start Phase IIb clinical trials in 2026 [5]. - RBD5044 (ApoC3): The second siRNA for ApoC3 to enter clinical stages, following Arrowhead [5]. - RBD1016 (HBV): Currently validating its drugability for HBV [5]. Market Position and Outlook - **Market Concerns**: There are market concerns regarding the drugability of FXI inhibitors. However, Rebio believes that FXI inhibitors have validated drugability in conditions such as stroke and post-knee replacement surgery. FXI siRNA is expected to tackle atrial fibrillation indications due to its higher target inhibition rate [6]. - **Catalysts for Growth**: Potential catalysts include industry data mapping for FXI inhibitors and ApoC3 siRNA, as well as the initiation of multiple Phase II clinical trials and data readouts for Rebio's small nucleic acid drugs [6]. - **Investment Rating**: The company is rated as outperforming the industry, with a target price of HKD 100.00, indicating a potential upside of 44.9% from the current stock price [6].

Core Viewpoint - CICC initiates coverage of Rebio Biotech-B (06938) with an "outperform" rating, setting a target price of HKD 100.0, indicating a potential upside of 44.9% from the current stock price [1][9]. Company Overview - Rebio is a global leader in small RNA drug development, possessing a proven and mature small RNA drug development platform [2][10]. - Since its establishment in 2007, the company has developed the GalNAc liver-targeting RiboGalSTAR platform and is expanding from liver-targeting to extrahepatic targeting [2][10]. - The company continuously iterates chemical modifications to enhance target specificity and sequence compatibility while reducing off-target effects, thereby improving efficacy and safety [2][10]. - As of the end of 2025, Rebio holds 473 patents and patent applications across major jurisdictions, establishing a comprehensive intellectual property portfolio [2][10]. - The company's R&D platform integrates the entire technical chain, ensuring efficiency in pipeline advancement from CMC production and early research to commercialization [2][10]. Clinical Assets - Rebio is one of the Chinese small RNA companies with the most clinical assets, having seven siRNA candidates in clinical stages as of the end of 2025, with four in Phase II [3][11]. - Key assets include RBD4059 (FXI), RBD5044 (ApoC3), and RBD1016 (HBV) [3][11]. - RBD4059 is the world's first and fastest clinical siRNA drug for treating thrombotic diseases, expected to enter Phase IIb clinical trials in 2026 [3][11]. - RBD5044 is the second siRNA targeting ApoC3 to enter clinical stages, following Arrowhead [3][11]. - RBD1016 is currently being evaluated for its drugability in HBV [3][11]. Market Perspective - The primary market concern is the drugability of FXI inhibitors; however, CICC believes that FXI inhibitors have demonstrated drugability in indications such as stroke and post-knee replacement surgery [4][12]. - FXI siRNA is expected to tackle atrial fibrillation indications due to its higher target inhibition rate [4][12]. Potential Catalysts - The industry is mapping data for FXI inhibitors and ApoC3 siRNA, with multiple Rebio small RNA drugs entering Phase II clinical trials and data readouts expected [5][13].

Core Viewpoint - CICC initiates coverage on RiboBio-B (06938) with an "outperform" rating, setting a target price of HKD 100.0, indicating a 44.9% upside potential from the current stock price [1] Group 1: Company Overview - RiboBio is a global leader in small RNA drug development, possessing a proven and mature small RNA drug development platform [1] - Since its establishment in 2007, the company has developed the GalNAc liver-targeting RiboGalSTAR platform and is expanding from liver-targeting to extrahepatic targeting [1] - The company continuously iterates chemical modifications to enhance target specificity and sequence compatibility while reducing off-target effects, thereby improving efficacy and safety [1] - As of the end of 2025, RiboBio holds 473 patents and patent applications across major jurisdictions, establishing a comprehensive intellectual property portfolio [1] - The company's R&D platform integrates the entire technology chain, ensuring efficiency in pipeline advancement from CMC production and early research to commercialization [1] Group 2: Clinical Assets - RiboBio is one of the Chinese small RNA companies with the most clinical assets, having 7 siRNA candidates in clinical stages as of the end of 2025, with 4 in Phase II [2] - Core assets include RBD4059 (FXI), RBD5044 (ApoC3), and RBD1016 (HBV) [2] - RBD4059 is the world's first and fastest clinical FXI siRNA drug for treating thrombotic diseases, expected to enter Phase IIb clinical trials in 2026 [2] - RBD5044 is the second siRNA targeting ApoC3 to enter clinical stages, following Arrowhead [2] - RBD1016 is currently being evaluated for its drugability in HBV [2] Group 3: Market Perspective - The main difference between the firm and the market is the belief in the drugability of FXI inhibitors, particularly for conditions like stroke and post-knee replacement surgery, which have validated drugability [3] - FXI siRNA is expected to tackle atrial fibrillation indications due to its higher target inhibition rate [3] Group 4: Potential Catalysts - Potential catalysts include data mapping for FXI inhibitors and ApoC3 siRNA, as well as the initiation of Phase II clinical trials and data readouts for multiple small RNA drugs from RiboBio [4]